Summary
Cannot evaluate alignment because the provided FDA label excerpts appear not to be actually matched against the user claims (the evaluation content included indicates no claim text was provided for assessment). Therefore, support/contradiction cannot be reliably determined from the supplied materials.
Category Scores
Accurate Statements
Siponimod is the active ingredient of MAYZENT.
Not verifiable from the provided excerpt-matching audit content.
Unsupported Statements
All 18 claims listed by the user (indications, mechanism, side effects, serious risks, and EMA approval) cannot be marked as supported or unsupported because the provided label-assertion assessment content indicates no claim text was evaluated against the label.
The supplied evaluation content states 'Supported: no / Contradicted: no / Mentioned: no' and 'No medical claim was provided to evaluate.' As a result, statement-level support cannot be determined.
Contradictions
Important Omissions
Statement-level label references for each of the user claims (e.g., whether each is explicitly supported by Indications (1), Adverse Reactions (6), Warnings (5), and Drug Interactions (7) in the provided excerpts).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because support/contradiction for multiple clinical claims (indications, adverse effects, and serious risks) cannot be determined from the supplied evaluation content, there is a high risk of inaccurate label alignment assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable
Primary Issue
The supplied materials do not contain a valid mapping/evaluation of each user claim against the label excerpts.
Suggested Improvement
Provide a response that explicitly evaluates each of the 18 user claims against the exact provided label excerpts (section and quote/paraphrase), or provide the full FDA label text and a per-claim support/contradiction determination.